Poor
Not Aligned
Patient Risk:
High
Summary
Only a limited portion of claims can be tied to the provided label text (indications; some adverse reactions topics). Most safety/side-effect frequency and multiple risk assertions are not supported by the supplied label excerpts, and key safety/counseling elements are not verifiable due to missing label sections in the input.
Category Scores
Accurate Statements
Lipitor is used to treat high cholesterol.
Supported by provided excerpt in 1 INDICATIONS AND USAGE (adjunct to diet for hypercholesterolemia/atherosclerotic risk context).
Lipitor can cause liver damage in some people.
Partially supported by provided excerpt in 6 ADVERSE REACTIONS referencing liver enzyme abnormalities (labeled hepatic adverse reaction topic).
Rhabdomyolysis is a rare but serious side effect of Lipitor.
Partially supported by provided excerpt in 6 ADVERSE REACTIONS referencing rhabdomyolysis and myopathy (severity supported; 'rare' and quantitative wording not verified).
Lipitor has been linked to an increased risk of muscle damage.
Partially supported by provided excerpt in 6 ADVERSE REACTIONS referencing rhabdomyolysis and myopathy.
Lipitor is a cholesterol-lowering medication.
Partially supported by provided excerpt context in 1 INDICATIONS AND USAGE (lipid-altering agent for hypercholesterolemia).
Unsupported Statements
Lipitor is also known as atorvastatin.
No support/definition for atorvastatin equivalence was provided in the supplied label excerpts.
Lipitor reduces the risk of heart disease.
No cardiovascular risk-reduction statement was supported by the provided label excerpts (only general indication/risk-factor intervention context was provided).
The most common side effects of Lipitor include muscle pain, affecting up to 10% of people who take the medication.
No label support provided for 'most common', 'up to 10%', or frequency of specific symptoms in the supplied excerpts.
Muscle pain from Lipitor may be accompanied by muscle weakness.
No label support provided for this specific symptom pairing.
Headache is a common side effect of Lipitor, affecting up to 5% of people who take the medication.
No label support provided for headache as a common adverse reaction or the 'up to 5%' incidence.
Diarrhea is a common side effect of Lipitor, affecting up to 5% of people who take the medication.
No label support provided for diarrhea as a common adverse reaction or the 'up to 5%' incidence.
Nausea is a common side effect of Lipitor, affecting up to 5% of people who take the medication.
No label support provided for nausea as a common adverse reaction or the 'up to 5%' incidence.
Fatigue is a common side effect of Lipitor, affecting up to 5% of people who take the medication.
No label support provided for fatigue as a common adverse reaction or the 'up to 5%' incidence.
Lipitor-related liver damage is particularly associated with people who have pre-existing liver disease.
No label support provided for this risk stratification.
Lipitor can cause kidney damage in some people.
No label support provided for kidney damage as a labeled adverse reaction in the supplied excerpts.
Lipitor-related kidney damage is particularly associated with people who have pre-existing kidney disease.
No label support provided for this risk stratification.
Rhabdomyolysis from Lipitor can cause muscle damage and kidney failure.
No label support provided for 'kidney failure' or these specific sequelae in the supplied excerpts.
Lipitor has been linked to an increased risk of developing type 2 diabetes.
No label support provided for diabetes risk in the supplied excerpts.
The increased risk of type 2 diabetes from Lipitor is particularly in people who are already at risk.
No label support provided for diabetes risk stratification.
Lipitor has been linked to an increased risk of cognitive impairment.
No label support provided for cognitive impairment.
The increased risk of cognitive impairment from Lipitor is particularly in older adults.
No label support provided for cognitive impairment or older-adult stratification.
The increased risk of muscle damage from Lipitor is particularly in people who take high doses or have pre-existing muscle disease.
No label support provided for these risk factors in the supplied excerpts.
Patients should not stop taking Lipitor without talking to their doctor first.
No label support provided for this specific counseling instruction in the supplied excerpts.
Taking Lipitor as directed by a doctor and not skipping doses can help minimize side effects.
No label support provided for the specific claim that adherence/non-skipping 'helps minimize side effects' in the supplied excerpts.
Contradictions
Important Omissions
Contraindications (including pregnancy-related contraindication language, if any) and other mandatory safety contraindication details.
Importance:
High
Boxed warning status and boxed warning text (if present in the current FDA label).
Importance:
High
Drug interaction warnings and concomitant-substance guidance required by labeled precautions.
Importance:
Moderate
Dosing and administration safety/adjustment instructions (dose modifications, monitoring requirements, and administration-specific precautions).
Importance:
Moderate
Complete adverse reaction profile including frequency wording and monitoring/management statements.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Multiple specific adverse-effect frequency/wording claims (e.g., 'common', 'up to 5%', 'up to 10%') and several serious risk claims (diabetes, cognitive impairment, kidney damage/kidney failure, risk stratification) are not supported by the supplied label excerpts, which could mislead about likelihood and safety counseling. Key label safety sections were not provided, preventing verification of major contraindications/warnings.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Many safety/side-effect and risk claims are unsupported by the provided label sections and include unverified quantitative frequency statements; multiple serious risks are asserted without supplied label support.
Suggested Improvement
Limit claims to what is explicitly supported by the provided label excerpts (or supply the missing FDA label sections, especially Warnings/Precautions, Drug Interactions, Contraindications, and full Adverse Reactions including incidence). Remove or rephrase unsupported frequency ('up to X%') and unverified risk associations (e.g., diabetes, cognitive impairment, kidney damage), and ensure counseling statements are directly supported by Patient Counseling Information text.